• Absci filed an initial beneficial ownership statement for Somaratne Ransi Mudalinayake, chief medical officer, head of R&D.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001672688-26-000128), on August 07, 2026, and is solely responsible for the information contained therein.